With the future of its generics and biosimilars business Sandoz finally decided, Novartis AG CEO Vas Narasimhan says the Swiss major has concluded its journey to become a focused innovative medicines company, but there will be no cash windfall to further boost the firm's R&D budget.
Following a strategic review that began last October, Novartis has chosen the option of a 100% spin off for Sandoz, separating the division into a new publicly traded standalone company
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?